Baidu
map

Nature COMMUN:解决多病者吃药的痛苦,新技术可以把一堆药打印到一张“糖果纸”上

2017-09-29 佚名 36 氪

吃药是一个痛苦的事情。最痛苦的事情还不在于药片的苦,而在于,一下子吃很多种药(比如说七八种)的话,拿这个药片那个胶囊的,很麻烦,如果上班的话,带着一堆药瓶子去公司,就更麻烦,时间一久,光吃药的麻烦劲儿就会让人厌倦,所以病没全好,有时候就把药停了。从小体弱多病的我,在这一点上深有感触。基于这种多病属性,密歇根大学研究人员开发的一种新技术,引起了我的兴趣。这种技术可以将多种药物打印在一次性的条装带或者



吃药是一个痛苦的事情。

最痛苦的事情还不在于药片的苦,而在于,一下子吃很多种药(比如说七八种)的话,拿这个药片那个胶囊的,很麻烦,如果上班的话,带着一堆药瓶子去公司,就更麻烦,时间一久,光吃药的麻烦劲儿就会让人厌倦,所以病没全好,有时候就把药停了。

从小体弱多病的我,在这一点上深有感触。

基于这种多病属性,密歇根大学研究人员开发的一种新技术,引起了我的兴趣。这种技术可以将多种药物打印在一次性的条装带或者贴片上,就像糖果纸那样。这项成果已经发表在《自然》的子刊《自然—通信》上。

在测试中,这些药物和传统的药物一样有效,可以破坏培养的癌细胞。关键的是,这种技术同时打印多种药物,对于每天服用很多处方药的患者来说,这要方便得多。

把需要吃的药打印到一张贴片上,一饮而尽,确实比来回开药瓶子要简洁很多,而且,去公司的话,不用带一堆药瓶子随身,这一点对上班族来说有更大的实用性。

这种技术的初衷本身也是如此:希望提高患者的依从性,老老实实地遵医嘱把该吃的药按时按量吃了。对于小孩来说,有了这种技术,给他们喂药的麻烦也要减少很多。

此外,它可以让药品更容易被运送到困难的地区,比如战区或农村地区,因为有些药品按照常规保存方法,在运输过程中很难让它们保持稳定。

而大肆宣传的个性化医疗也要求有一种简单、低成本、本地化的方式,来生产针对个人的少量物质。

因此,理论上说,这种技术也拥有个性化医疗的应用前景。

研究人员使用了“蒸汽喷射打印”(vapor jet printing)技术,来开发他们的新药物制造技术。这使得高分辨率的打印,能够被精确地打印到一个精细的晶体结构上。

具体来说,在这种技术中,活性成分被蒸发掉,然后再与一股像氮气这样样的惰性气体混合在一起。随后,药物会随气体一起传播,然后在冷却的表面凝结成一层薄薄的结晶膜。

这种排列会使得药物的溶解变得更加容易。

当然,这项技术还需要数年时间,才能打印出面向大众的药物。

不过,短期内,它可能会开始在制药公司内部使用,这些公司可以利用这种贴片技术,快速药物生产来加速临床试验。

制药公司面临的主要挑战之一是对人类临床测试的速度,这项技术为加快新药的评估提供了一种新的方法。

但是研究人员希望,有一天,这项技术可以在像糖果纸一样的卷纸上打印大量的药物。

听起来很美好的样子哦。

不过,还是祝愿大家、也祝愿我自己远离疾病吧。就我个人经验来说,生病这种事,只能是病好了之后给别人提供段子,让大家开心一下,可是这种生产段子的方式效率太低了,费时费力折磨身体还花钱,实在犯不上。看别人倒霉也一样可以创造段子嘛,为什么非要自己倒霉呢,对吧?

所以,还是健健康康地活着吧,身体倍儿棒,呼吸吐纳之间,感觉风清月朗、碧海长空,挺好。

原始出处:

Olga Shalev,et al.Printing of small molecular medicines from the vapor phase.Nature Communications 8, Article number: 711 (2017)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882477, encodeId=4e1118824e713, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 18 00:58:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903775, encodeId=e8f91903e75a8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Sep 14 02:58:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087135, encodeId=1351208e13568, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 10 21:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248780, encodeId=a83c248e8067, content=好好努力学习好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Sep 29 11:39:23 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248768, encodeId=c095248e68be, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Sep 29 10:41:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-02-18 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882477, encodeId=4e1118824e713, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 18 00:58:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903775, encodeId=e8f91903e75a8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Sep 14 02:58:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087135, encodeId=1351208e13568, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 10 21:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248780, encodeId=a83c248e8067, content=好好努力学习好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Sep 29 11:39:23 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248768, encodeId=c095248e68be, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Sep 29 10:41:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882477, encodeId=4e1118824e713, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 18 00:58:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903775, encodeId=e8f91903e75a8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Sep 14 02:58:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087135, encodeId=1351208e13568, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 10 21:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248780, encodeId=a83c248e8067, content=好好努力学习好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Sep 29 11:39:23 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248768, encodeId=c095248e68be, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Sep 29 10:41:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-07-10 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882477, encodeId=4e1118824e713, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 18 00:58:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903775, encodeId=e8f91903e75a8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Sep 14 02:58:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087135, encodeId=1351208e13568, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 10 21:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248780, encodeId=a83c248e8067, content=好好努力学习好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Sep 29 11:39:23 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248768, encodeId=c095248e68be, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Sep 29 10:41:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 忠诚向上

    好好努力学习好好努力学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1882477, encodeId=4e1118824e713, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 18 00:58:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903775, encodeId=e8f91903e75a8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Fri Sep 14 02:58:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087135, encodeId=1351208e13568, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 10 21:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248780, encodeId=a83c248e8067, content=好好努力学习好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Sep 29 11:39:23 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248768, encodeId=c095248e68be, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Fri Sep 29 10:41:00 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 中医痴

    不错的.学习了.谢谢分享.

    0

相关资讯

这39个药,将遭大砍价(附名单)

这39个药,将遭大砍价(附名单) 昨日(23日),重庆药品交易所公布《关于开展重庆市公立医院非医保药品联合议价工作的通知》,宣布包括氨酚麻美干混悬剂、蒲地蓝等在内的39个品种开始议价,涉及36家生产(申报)企业。

从医药代表的被迫转型 看一颗药的奇幻之旅

最后回归到两个词,“渠道多元,融合明显”。

上海缺这17个药,医院高价买!

招标砍价一片繁忙,降降降!但有些药品却逆流而上,价格不断上涨,一次比一次高

全球昂贵的五种药 它们凭什么卖这么贵!

近日,全球最贵药物Glybera被其研发商荷兰生物技术公司uniQure叫停,并宣布将撤市。以Glybera为首的全球最贵药,费用每年至少几十万美元,相当于一辆超级跑车的价格。高昂的天价和暗淡的市场令这些药物陷入“有价无市”的尴尬境遇。Glybera世界首个基因药物药价:101万美元/年企业:荷兰的生物科技公司UniQureGlybera是针对治疗脂蛋白脂酶缺乏症的药物,每年的花费高达101万美元

Neurotoxicol:鲜花施药影响儿童神经行为

在近期《神经毒理学》上发表的一篇论文中,美国加利福尼亚大学圣地亚哥分校医学院的研究人员和厄瓜多尔、明尼苏达的同行共同发现,儿童改变短期神经行为与农药施药高峰季相关,也就是母亲节鲜花收获之时。这项研究调查的儿童不从事农业生产但住在农业社区里。

你知道吗?我们用的有些药是别人身体里的一部分

李长清,中国医学科学院 北京协和医学院输血研究所科技处处长、教授/主任技师、博士生导师。“当我们碰到体弱多病的人时,常常会听到别人议论他就是个‘药罐子’,其实,当我们身体状况比较好的时候,我们还可以生产药物。”李长清介绍,来自我们健康人血浆的药物常说的主要是人血白蛋白、免疫球蛋白和凝血因子三大类,其实还有第四类:其他,比如一些抗凝蛋白因子成分。人血白蛋白俗称“救命药”,传说中的神药,当一些因失

Baidu
map
Baidu
map
Baidu
map